Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations
Background: Lipoprotein(a) is positively related to cardiovascular events in patients with coronary artery disease (CAD). Given that lipoprotein(a) has a prothrombotic effect, prolonged dual antiplatelet therapy (DAPT) might have a beneficial effect on reducing ischemic events in patients with eleva...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.807925/full |
| _version_ | 1819177861365366784 |
|---|---|
| author | Kongyong Cui Kongyong Cui Kongyong Cui Kongyong Cui Hao-Yu Wang Hao-Yu Wang Hao-Yu Wang Hao-Yu Wang Dong Yin Dong Yin Dong Yin Dong Yin Chenggang Zhu Chenggang Zhu Chenggang Zhu Chenggang Zhu Weihua Song Weihua Song Weihua Song Weihua Song Hongjian Wang Hongjian Wang Hongjian Wang Hongjian Wang Lei Jia Lei Jia Lei Jia Lei Jia Dong Zhang Dong Zhang Dong Zhang Dong Zhang Chenxi Song Chenxi Song Chenxi Song Chenxi Song Lei Feng Lei Feng Lei Feng Lei Feng Kefei Dou Kefei Dou Kefei Dou Kefei Dou |
| author_facet | Kongyong Cui Kongyong Cui Kongyong Cui Kongyong Cui Hao-Yu Wang Hao-Yu Wang Hao-Yu Wang Hao-Yu Wang Dong Yin Dong Yin Dong Yin Dong Yin Chenggang Zhu Chenggang Zhu Chenggang Zhu Chenggang Zhu Weihua Song Weihua Song Weihua Song Weihua Song Hongjian Wang Hongjian Wang Hongjian Wang Hongjian Wang Lei Jia Lei Jia Lei Jia Lei Jia Dong Zhang Dong Zhang Dong Zhang Dong Zhang Chenxi Song Chenxi Song Chenxi Song Chenxi Song Lei Feng Lei Feng Lei Feng Lei Feng Kefei Dou Kefei Dou Kefei Dou Kefei Dou |
| author_sort | Kongyong Cui |
| collection | DOAJ |
| description | Background: Lipoprotein(a) is positively related to cardiovascular events in patients with coronary artery disease (CAD). Given that lipoprotein(a) has a prothrombotic effect, prolonged dual antiplatelet therapy (DAPT) might have a beneficial effect on reducing ischemic events in patients with elevated lipoprotein(a) levels after percutaneous coronary intervention (PCI). We performed this study to assess the efficacy and safety of prolonged DAPT (>1 year) in this population.Methods: We evaluated a total of 3,025 CAD patients with elevated lipoprotein(a) levels who were event-free at 1 year after PCI from the prospective Fuwai PCI Registry, of which 913 received DAPT ≤ 1 year and 2,112 received DAPT>1 year. The primary endpoint was major adverse cardiovascular and cerebrovascular event (MACCE), defined as a composite of all-cause death, myocardial infarction or stroke.Results: After a median follow-up of 2.4 years, patients who received DAPT>1 year were associated with lower risks of MACCE compared with DAPT ≤ 1 year (1.6 vs. 3.8%; hazard ratio [HR] 0.383, 95% confidence interval [CI] 0.238–0.616), which was primarily driven by the lower all-cause mortality (0.2 vs. 2.3%; HR 0.078, 95% CI 0.027–0.227). In addition, DAPT>1 year was also associated with lower risks of cardiac death, and definite/probable stent thrombosis than those who received DAPT ≤ 1 year (P < 0.05). Conversely, no difference was found between the two groups in terms of clinically relevant bleeding. Similar results were observed in multivariate Cox regression analysis and inverse probability of treatment weighting analysis.Conclusions: In patients with elevated lipoprotein(a) concentrations after PCI, prolonged DAPT (>1 year) reduced ischemic cardiovascular events, including MACCE, all-cause mortality, cardiac mortality, and definite/probable stent thrombosis, without increase in clinically relevant bleeding risk compared with ≤ 1-year DAPT. Lipoprotein(a) levels might be a new important consideration when deciding the duration of DAPT after PCI. |
| first_indexed | 2024-12-22T21:33:23Z |
| format | Article |
| id | doaj.art-8bf1b93ba11040d58aa4b9d51d64a37b |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-22T21:33:23Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-8bf1b93ba11040d58aa4b9d51d64a37b2022-12-21T18:11:51ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2021-12-01810.3389/fcvm.2021.807925807925Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) ConcentrationsKongyong Cui0Kongyong Cui1Kongyong Cui2Kongyong Cui3Hao-Yu Wang4Hao-Yu Wang5Hao-Yu Wang6Hao-Yu Wang7Dong Yin8Dong Yin9Dong Yin10Dong Yin11Chenggang Zhu12Chenggang Zhu13Chenggang Zhu14Chenggang Zhu15Weihua Song16Weihua Song17Weihua Song18Weihua Song19Hongjian Wang20Hongjian Wang21Hongjian Wang22Hongjian Wang23Lei Jia24Lei Jia25Lei Jia26Lei Jia27Dong Zhang28Dong Zhang29Dong Zhang30Dong Zhang31Chenxi Song32Chenxi Song33Chenxi Song34Chenxi Song35Lei Feng36Lei Feng37Lei Feng38Lei Feng39Kefei Dou40Kefei Dou41Kefei Dou42Kefei Dou43Cardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaCoronary Heart Disease Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Beijing, ChinaNational Clinical Research Center for Cardiovascular Diseases, Beijing, ChinaCardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaCoronary Heart Disease Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Beijing, ChinaNational Clinical Research Center for Cardiovascular Diseases, Beijing, ChinaCardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaCoronary Heart Disease Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Beijing, ChinaNational Clinical Research Center for Cardiovascular Diseases, Beijing, ChinaCardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaCoronary Heart Disease Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Beijing, ChinaNational Clinical Research Center for Cardiovascular Diseases, Beijing, ChinaCardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaCoronary Heart Disease Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Beijing, ChinaNational Clinical Research Center for Cardiovascular Diseases, Beijing, ChinaCardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaCoronary Heart Disease Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Beijing, ChinaNational Clinical Research Center for Cardiovascular Diseases, Beijing, ChinaCardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaCoronary Heart Disease Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Beijing, ChinaNational Clinical Research Center for Cardiovascular Diseases, Beijing, ChinaCardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaCoronary Heart Disease Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Beijing, ChinaNational Clinical Research Center for Cardiovascular Diseases, Beijing, ChinaCardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaCoronary Heart Disease Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Beijing, ChinaNational Clinical Research Center for Cardiovascular Diseases, Beijing, ChinaCardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaCoronary Heart Disease Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Beijing, ChinaNational Clinical Research Center for Cardiovascular Diseases, Beijing, ChinaCardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaCoronary Heart Disease Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Cardiovascular Disease, Beijing, ChinaNational Clinical Research Center for Cardiovascular Diseases, Beijing, ChinaBackground: Lipoprotein(a) is positively related to cardiovascular events in patients with coronary artery disease (CAD). Given that lipoprotein(a) has a prothrombotic effect, prolonged dual antiplatelet therapy (DAPT) might have a beneficial effect on reducing ischemic events in patients with elevated lipoprotein(a) levels after percutaneous coronary intervention (PCI). We performed this study to assess the efficacy and safety of prolonged DAPT (>1 year) in this population.Methods: We evaluated a total of 3,025 CAD patients with elevated lipoprotein(a) levels who were event-free at 1 year after PCI from the prospective Fuwai PCI Registry, of which 913 received DAPT ≤ 1 year and 2,112 received DAPT>1 year. The primary endpoint was major adverse cardiovascular and cerebrovascular event (MACCE), defined as a composite of all-cause death, myocardial infarction or stroke.Results: After a median follow-up of 2.4 years, patients who received DAPT>1 year were associated with lower risks of MACCE compared with DAPT ≤ 1 year (1.6 vs. 3.8%; hazard ratio [HR] 0.383, 95% confidence interval [CI] 0.238–0.616), which was primarily driven by the lower all-cause mortality (0.2 vs. 2.3%; HR 0.078, 95% CI 0.027–0.227). In addition, DAPT>1 year was also associated with lower risks of cardiac death, and definite/probable stent thrombosis than those who received DAPT ≤ 1 year (P < 0.05). Conversely, no difference was found between the two groups in terms of clinically relevant bleeding. Similar results were observed in multivariate Cox regression analysis and inverse probability of treatment weighting analysis.Conclusions: In patients with elevated lipoprotein(a) concentrations after PCI, prolonged DAPT (>1 year) reduced ischemic cardiovascular events, including MACCE, all-cause mortality, cardiac mortality, and definite/probable stent thrombosis, without increase in clinically relevant bleeding risk compared with ≤ 1-year DAPT. Lipoprotein(a) levels might be a new important consideration when deciding the duration of DAPT after PCI.https://www.frontiersin.org/articles/10.3389/fcvm.2021.807925/fulllipoprotein(a) [Lp(a)]coronary artery diseasepercutaneous coronary intervention (or PCI)drug-eluting stent (DES)DAPT (dual antiplatelet therapy)clinical outcome |
| spellingShingle | Kongyong Cui Kongyong Cui Kongyong Cui Kongyong Cui Hao-Yu Wang Hao-Yu Wang Hao-Yu Wang Hao-Yu Wang Dong Yin Dong Yin Dong Yin Dong Yin Chenggang Zhu Chenggang Zhu Chenggang Zhu Chenggang Zhu Weihua Song Weihua Song Weihua Song Weihua Song Hongjian Wang Hongjian Wang Hongjian Wang Hongjian Wang Lei Jia Lei Jia Lei Jia Lei Jia Dong Zhang Dong Zhang Dong Zhang Dong Zhang Chenxi Song Chenxi Song Chenxi Song Chenxi Song Lei Feng Lei Feng Lei Feng Lei Feng Kefei Dou Kefei Dou Kefei Dou Kefei Dou Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations Frontiers in Cardiovascular Medicine lipoprotein(a) [Lp(a)] coronary artery disease percutaneous coronary intervention (or PCI) drug-eluting stent (DES) DAPT (dual antiplatelet therapy) clinical outcome |
| title | Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations |
| title_full | Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations |
| title_fullStr | Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations |
| title_full_unstemmed | Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations |
| title_short | Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations |
| title_sort | benefit and risk of prolonged dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents in patients with elevated lipoprotein a concentrations |
| topic | lipoprotein(a) [Lp(a)] coronary artery disease percutaneous coronary intervention (or PCI) drug-eluting stent (DES) DAPT (dual antiplatelet therapy) clinical outcome |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2021.807925/full |
| work_keys_str_mv | AT kongyongcui benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT kongyongcui benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT kongyongcui benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT kongyongcui benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT haoyuwang benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT haoyuwang benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT haoyuwang benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT haoyuwang benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT dongyin benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT dongyin benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT dongyin benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT dongyin benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT chenggangzhu benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT chenggangzhu benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT chenggangzhu benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT chenggangzhu benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT weihuasong benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT weihuasong benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT weihuasong benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT weihuasong benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT hongjianwang benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT hongjianwang benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT hongjianwang benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT hongjianwang benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT leijia benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT leijia benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT leijia benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT leijia benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT dongzhang benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT dongzhang benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT dongzhang benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT dongzhang benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT chenxisong benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT chenxisong benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT chenxisong benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT chenxisong benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT leifeng benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT leifeng benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT leifeng benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT leifeng benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT kefeidou benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT kefeidou benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT kefeidou benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations AT kefeidou benefitandriskofprolongeddualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsinpatientswithelevatedlipoproteinaconcentrations |